Canada - français - Health Canada

sanofi-aventis canada inc - rasburicase - poudre pour solution - 1.5mg - rasburicase 1.5mg - enzymes

Canada - français - Health Canada

sanofi-aventis canada inc - rasburicase - poudre pour solution - 7.5mg - rasburicase 7.5mg - enzymes

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - rasburicasum - poudre et solvant pour solution à diluer pour perfusion - praeparatio sicca: rasburicasum 1.5 mg, alaninum, mannitolum, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dodecahydricus, pro vitro corresp. natrium max. 2.1 mg. solvens: poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - hyperuricémie - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - rasburicasum - poudre et solvant pour solution à diluer pour perfusion - praeparatio sicca: rasburicasum 7.5 mg, alaninum, mannitolum, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dodecahydricus, pro vitro corresp. natrium max. 10.5 mg. solvens: poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 5 ml. - hyperuricémie - biotechnologika

Union européenne - français - EMA (European Medicines Agency)

sanofi winthrop industrie - rasburicase - hyperuricémie - tous les autres produits thérapeutiques - traitement et prophylaxie de l’hyperuricémie aiguë, afin d’éviter une insuffisance rénale aiguë, chez les adultes, enfants et adolescents (âgés de 0 à 17 ans) avec malignité hématologique avec une charge élevée de tumeurs et au risque de lyse tumorale rapide ou retrait à début de la chimiothérapie.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

sanofi-aventis france - rasburicase - poudre et solvant pour solution à diluer pour perfusion

Union européenne - français - EMA (European Medicines Agency)

pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Union européenne - français - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosuppresseurs - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Union européenne - français - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunosuppresseurs - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).